Vlad Coric, Biohaven CEO (Jordan Sirek/Bloomberg via Getty Images)
Pfizer buys Biohaven for $11.6B, going all in on CGRP migraine drug portfolio
Pfizer has found a use for a chunk of its Covid windfall, agreeing to buy Biohaven and its migraine drug Nurtec for $11.6 billion. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
